Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001000694-24-000043
Filing Date
2024-11-12
Accepted
2024-11-12 16:08:10
Documents
80
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nvax-20240930.htm   iXBRL 10-Q 1228377
2 EX-31.1 nvax-20240930xex311.htm EX-31.1 10615
3 EX-31.2 nvax-20240930xex312.htm EX-31.2 11962
4 EX-32.1 nvax-20240930xex321.htm EX-32.1 6283
5 EX-32.2 nvax-20240930xex322.htm EX-32.2 6366
11 nvax-20240930_g1.jpg GRAPHIC 559155
  Complete submission text file 0001000694-24-000043.txt   8440765

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nvax-20240930.xsd EX-101.SCH 51544
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nvax-20240930_cal.xml EX-101.CAL 56160
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nvax-20240930_def.xml EX-101.DEF 284978
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nvax-20240930_lab.xml EX-101.LAB 678861
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nvax-20240930_pre.xml EX-101.PRE 490397
83 EXTRACTED XBRL INSTANCE DOCUMENT nvax-20240930_htm.xml XML 878874
Mailing Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878
Business Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-26770 | Film No.: 241448095
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)